Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial-Reference-Cited by-同舟云学术

Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial

Published:2001-05-14 Issue:5 Volume:47 Page:391-396
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:
Short-container-title:Cancer Chemotherapy and Pharmacology

Author:

Donadio M.,Manzin E.,Berruti A.,Bottini A.,Gorzegno G.,Danese S.,DeFabiani E.,Sarobba M.G.,Lorusso V.,Castiglione F.,Moro G.,Bertetto O.,Bumma C.,Dogliotti L.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s002800000247.pdf

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Presentation and Management of Hand–Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast Cancer;The Oncologist;2011-10-20

2. Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy;European Journal of Cancer Care;2009-03

3. Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS);Journal of Orthopaedic Research;2005-09

4. Oral administration of paclitaxel affects the distribution and metabolism of 2-aminofluorene in various tissues of Sprague-Dawley rats;Phytomedicine;2005-08

5. Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy;British Journal of Cancer;2004-03